Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen Inc.
CELGCelgene Corporation
GILDGilead Sciences, Inc.
BIIBBiogen Inc.
NKTRNektar Therapeutics
REGNRegeneron Pharmaceuticals, Inc.
VRTXVertex Pharmaceuticals Incorporated
ALXNAlexion Pharmaceuticals, Inc.
AAgilent Technologies, Inc.
ILMNIllumina, Inc.
EXASExact Sciences Corporation
INCYIncyte Corporation
BLUEBluebird Bio, Inc.
SRPTSarepta Therapeutics, Inc.
BMRNBioMarin Pharmaceutical Inc.

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It offers product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder, which is a type of female sexual dysfunction, defined as low desire with associated distress. It also offers drug candidates and development programs for cardiovascular diseases and inflammatory diseases. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.